ArticleClinical journal of gastroenterology2010
Interferon and nucleoside analog combination therapy for hepatitis B.
Article in Clinical journal of gastroenterology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interferon therapy has several advantages over nucleoside or nucleotide analog therapy: finite duration, durable treatment response, and no viral resistance. However, it is only effective in about 30% of patients. To improve its efficacy, the combination of interferon and nucleoside/nucleotide analogs may facilitate additive or synergistic effects. This is because interferon and nucleoside/nucleotide analogs have different mechanisms of action. Recent studies demonstrate that concomitant use of lamivudine and peginterferon does not improve biochemical and virological responses compared with peginterferon monotherapy. By contrast, sequential or staggered administration of lamivudine and interferon appears to have some benefits over monotherapies. There is a paucity of data on interferon combined with drugs other than lamivudine, such as adefovir and entecavir. Although combination therapies have the potential to improve efficacy against hepatitis-B virus, it is unclear how interferon should be combined with other drugs or which patients should be treated with combination therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.